FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1582684482> ?p ?o ?g. }

• W1582684482 endingPage "299" @default.
• W1582684482 startingPage "290" @default.
• W1582684482 abstract "Abstract Objectives: The aim of the study was to investigate the effect of bortezomib on osteoblast proliferation and differentiation, as well as on bone matrix deposition for the first time in bisphosphonate‐naïve, previously untreated patients with myeloma. Methods: Twenty newly diagnosed patients received four cycles of bortezomib treatment, initially as monotherapy and then combined with a glucocorticoid from cycle two to four. Bone remodeling markers were monitored closely during treatment. Furthermore, the effects of bortezomib and a glucocorticoid on immature and mature osteoblasts were also studied in vitro . Results: Treatment with bortezomib caused a significant increase in bone‐specific alkaline phosphatase and pro‐collagen type I N‐terminal propeptide, a novel bone formation marker. The addition of a glucocorticoid resulted in a transient decrease in collagen deposition. In vitro bortezomib induced osteoblast proliferation and differentiation. Differentiation but not proliferation was inhibited by glucocorticoid treatment. Conclusions: Bortezomib used as first‐line treatment significantly increased collagen deposition in patients with multiple myeloma and osteolytic lesions, but the addition of a glucocorticoid to the treatment transiently inhibited the positive effect of bortezomib, suggesting that bortezomib may result in better healing of osteolytic lesions when used without glucocorticoids in patients that have obtained remission with a previous therapy. The potential bone‐healing properties of single‐agent bortezomib are currently being explored in a clinical study in patients who have undergone high‐dose therapy and autologous stem cell transplantation." @default.
• W1582684482 created "2016-06-24" @default.
• W1582684482 creator A5028707750 @default.
• W1582684482 creator A5029812406 @default.
• W1582684482 creator A5049717703 @default.
• W1582684482 creator A5058033035 @default.
• W1582684482 creator A5060699933 @default.
• W1582684482 creator A5063069301 @default.
• W1582684482 creator A5076872867 @default.
• W1582684482 creator A5078746397 @default.
• W1582684482 date "2010-06-07" @default.
• W1582684482 modified "2023-10-17" @default.
• W1582684482 title "First-line treatment with bortezomib rapidly stimulates both osteoblast activity and bone matrix deposition in patients with multiple myeloma, and stimulates osteoblast proliferation and differentiation in vitro" @default.
• W1582684482 cites W126207357 @default.
• W1582684482 cites W1842497498 @default.
• W1582684482 cites W1932993947 @default.
• W1582684482 cites W1968257416 @default.
• W1582684482 cites W1968326919 @default.
• W1582684482 cites W1971470705 @default.
• W1582684482 cites W1972705137 @default.
• W1582684482 cites W1973328408 @default.
• W1582684482 cites W1988977449 @default.
• W1582684482 cites W1991753648 @default.
• W1582684482 cites W1992422220 @default.
• W1582684482 cites W1995238317 @default.
• W1582684482 cites W1998297722 @default.
• W1582684482 cites W1999077925 @default.
• W1582684482 cites W2001313880 @default.
• W1582684482 cites W2017105628 @default.
• W1582684482 cites W2025707250 @default.
• W1582684482 cites W2029782351 @default.
• W1582684482 cites W2034528005 @default.
• W1582684482 cites W2036078949 @default.
• W1582684482 cites W2038329170 @default.
• W1582684482 cites W2039215669 @default.
• W1582684482 cites W2043295936 @default.
• W1582684482 cites W2044436186 @default.
• W1582684482 cites W2048709843 @default.
• W1582684482 cites W2062076773 @default.
• W1582684482 cites W2066000727 @default.
• W1582684482 cites W2069627659 @default.
• W1582684482 cites W2079007861 @default.
• W1582684482 cites W2082870980 @default.
• W1582684482 cites W2082877846 @default.
• W1582684482 cites W2087255769 @default.
• W1582684482 cites W2088332104 @default.
• W1582684482 cites W2090582753 @default.
• W1582684482 cites W2097878023 @default.
• W1582684482 cites W2108595411 @default.
• W1582684482 cites W2160088903 @default.
• W1582684482 cites W2167801466 @default.
• W1582684482 cites W2167859307 @default.
• W1582684482 cites W2325302070 @default.
• W1582684482 cites W2407107826 @default.
• W1582684482 cites W4244239178 @default.
• W1582684482 doi "https://doi.org/10.1111/j.1600-0609.2010.01485.x" @default.
• W1582684482 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2970902" @default.
• W1582684482 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20528908" @default.
• W1582684482 hasPublicationYear "2010" @default.
• W1582684482 type Work @default.
• W1582684482 sameAs 1582684482 @default.
• W1582684482 citedByCount "48" @default.
• W1582684482 countsByYear W15826844822012 @default.
• W1582684482 countsByYear W15826844822013 @default.
• W1582684482 countsByYear W15826844822014 @default.
• W1582684482 countsByYear W15826844822015 @default.
• W1582684482 countsByYear W15826844822016 @default.
• W1582684482 countsByYear W15826844822017 @default.
• W1582684482 countsByYear W15826844822018 @default.
• W1582684482 countsByYear W15826844822019 @default.
• W1582684482 countsByYear W15826844822020 @default.
• W1582684482 countsByYear W15826844822021 @default.
• W1582684482 countsByYear W15826844822023 @default.
• W1582684482 crossrefType "journal-article" @default.
• W1582684482 hasAuthorship W1582684482A5028707750 @default.
• W1582684482 hasAuthorship W1582684482A5029812406 @default.
• W1582684482 hasAuthorship W1582684482A5049717703 @default.
• W1582684482 hasAuthorship W1582684482A5058033035 @default.
• W1582684482 hasAuthorship W1582684482A5060699933 @default.
• W1582684482 hasAuthorship W1582684482A5063069301 @default.
• W1582684482 hasAuthorship W1582684482A5076872867 @default.
• W1582684482 hasAuthorship W1582684482A5078746397 @default.
• W1582684482 hasBestOaLocation W15826844821 @default.
• W1582684482 hasConcept C126322002 @default.
• W1582684482 hasConcept C134018914 @default.
• W1582684482 hasConcept C143998085 @default.
• W1582684482 hasConcept C185592680 @default.
• W1582684482 hasConcept C202751555 @default.
• W1582684482 hasConcept C2776169692 @default.
• W1582684482 hasConcept C2776364478 @default.
• W1582684482 hasConcept C2776541429 @default.
• W1582684482 hasConcept C2777478702 @default.
• W1582684482 hasConcept C2778260815 @default.
• W1582684482 hasConcept C2780841215 @default.
• W1582684482 hasConcept C502942594 @default.
• W1582684482 hasConcept C55493867 @default.
• W1582684482 hasConcept C71924100 @default.
• W1582684482 hasConceptScore W1582684482C126322002 @default.

• next